Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development-Reference-Cited by-同舟云学术

Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development

Published:2016-03 Issue:3 Volume:60 Page:1177-1182
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nuermberger Eric¹,Sizemore Christine²,Romero Klaus³,Hanna Debra³

Affiliation:

1. Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA

2. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, USA

3. Critical Path Institute, Tucson, Arizona, USA

Abstract

ABSTRACT Novel tuberculosis (TB) drug regimens are urgently needed, and their development will be enabled by improved preclinical approaches that more effectively inform and ensure safe selection of clinical candidates and drug combination/regimens. An evidence-based approach for the assessment of nonclinical models supporting TB drug development has been proposed by a joint partnership between the National Institute of Allergy and Infectious Diseases (NIAID) and the Critical Path to TB Drug Regimens (CPTR) Consortium.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02041-15

Reference18 articles.

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.

2. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig

3. Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia

4. Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis

5. Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical–genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy;Proceedings of the National Academy of Sciences;2022-04-05

2. Chemical-genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy;2021-04-09

3. Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future;Clinical Pharmacology & Therapeutics;2021-03-09

4. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis;Annual Review of Pharmacology and Toxicology;2021-01-06

5. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor;Antimicrobial Agents and Chemotherapy;2020-05-21